| 中文名称 | 维甲酰酚胺 |
| 英文名称 | 4-HYDROXYPHENYLRETINAMIDE |
| CAS号 | 65646-68-6 |
| 分子式 | C26H33NO2 |
| 分子量 | 391.55 |
| EINECS号 | 200-256-5 |
| 熔点 | 162-163°C |
| 沸点 | 597.6±42.0 °C(Predicted) |
| 密度 | 1.081±0.06 g/cm3(Predicted) |
| 溶解度 | 可溶于氯仿（少许）、甲醇（少许） |
| 形态 | 橙色固体 |
| 酸度系数(pKa) | 9.98±0.26(Predicted) |
| 颜色 | 粘黄色 |
| 最大波长(λmax) | 362nm(MeOH)(lit.) |
| 默克索引编号 | 14,3998 |
| 稳定性 | 对光敏感，应避光保存 |
| 危险品标志 | T |
| 危险类别码 | 60-61-20/21/22-36/37/38 |
| 安全说明 | 53-26-36/37/39-45-52 |
| WGK Germany | 3 |
| RTECS号 | VH6420000 |
| 海关编码 | 2924297099 |
Fenretinide (4-HPR) exerts not just acute but also long term antitumor activity in selected T-ALL cell lines. Fenretinide inhibits DES activity in CCRF-CEM leukemia cells in a dose and time dependent manner, leading to a concomitant increase of the endogenous cellular dhCer content. Fenretinide (3 μM)-induced dhCer accumulation in both CCRF-CEM and Jurkat cells. Ceramide inhibition with fenretinide protects insulin signaling. Fenretinide prevents lipid-induced reductions in insulin-stimulated glucose uptake. Fenretinide inhibits OVCAR-5 cell proliferation and viability at concentrations higher than 1 microM, with 70-90% growth inhibition at 10 microM. Fenretinide (1 microM) significantly inhibits OVCAR-5 invasion after 3 days preincubation. Endothelial cells treated with 1 microM 4-HPR fails to form tubes, but forms small cellular aggregates.
Fenretinide (4-HPR) (10 mg/kg, i.p.) selectively inhibits ceramide accumulation HFD-fed male C57Bl/6 mice. Fenretinide treatment improves glucose tolerance and insulin sensitivity as determined by both glucose and insulin tolerance tests. Addition of 25 mg/kg ketoconazole to Fenretinide in NOD/SCID mice increased 4-HPR plasma levels.
